In December 2014, Steve Daly joined Adocia in the newly created role of United States General Manager. Adocia is a clinical-stage, French biotech focused on affordable innovation by unlocking novel clinical attributes of already-approved peptides and proteins. Aside from day- to-day operations at Adocia USA, Steve is responsible, in whole or in part, for Business Development, Investor Relations, and Scientific Community Engagement. Before joining Adocia, Steve served in senior roles for the commercialization of therapeutics in the diabetes and metabolism fields at companies such as Amylin Pharmaceuticals (exenatide, pramlintide), Halozyme (hyaluronidase), and Affymax (peginesatide). Prior to nearly 14 years of experience in diabetes and metabolism, Steve held portfolio planning and commercialization roles in the generic and biosimilar marketplace for Baxter International and Sicor, a division of Teva Pharmaceuticals.